Inosi Therapeutics announces $968,192 in TTRA funding with support from IP Group and BioCurate
Posted: 23 June 2025 Inosi Therapeutics was awarded a $968,192 funding package from the Targeted Translation Research Accelerator (TTRA) initiative to advance its investigational treatment for Diabetic Kidney Disease into Investigational New Drug (IND)-enabling studies. The grant was…
MTPConnect announces $12 million investment in Heart Disease and Diabetes innovations
Posted: 23 June 2025 A substantial investment of $12.07 million was announced by MTPConnect to support 14 domestic life science companies developing innovative medical devices and pharmaceuticals aimed at reducing the impact of cardiovascular disease and diabetes (types…
WEHI researchers announce breakthrough in Long COVID treatment
Posted: 23 June 2025 A groundbreaking study was conducted by scientists at the Walter and Eliza Hall Institute (WEHI), revealing a novel drug compound that prevented long COVID symptoms in mice. This landmark discovery was anticipated to pave…
BioMelbourne Network launches its strategic plan to amplify Victoria’s health technologies sector impacts
Posted: 19 June 2025 Media Release BioMelbourne Network launches its strategic plan to amplify Victoria’s health technologies sector impacts Melbourne. BioMelbourne Network, Victoria’s peak industry body for health technologies sector, has today launched its new Strategic Plan…
Radium Capital unleashes $400m war chest for Aussie innovators
Posted: 13 June 2025 Radium Capital, Australia’s leader in R&D finance, has announced plans to lend $400 million to Australian innovators over the next 12 months. Radium Capital has deployed more than $900 million to companies undertaking research…
Telix Pharmaceuticals launches new Prostate Cancer Imaging Agent in U.S.
Posted: 13 June 2025 Telix Pharmaceuticals Limited announced that its next-generation PSMA-PET imaging agent for prostate cancer, Gozellix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection), had become commercially available nationwide in the United States (U.S.). Kevin…
Chimeric Therapeutics Receives $2.5 Million Advance on FY25 R&D Tax Incentive
Posted: 12 June 2025 Chimeric Therapeutics Limited (ASX:CHM), an Australian leader in cell therapy, announced the receipt of $2,500,000 from Endpoints Capital under a funding facility secured against the anticipated FY25 Research and Development Tax Incentive (RDTI). The…
Akaal Pharma Pty Ltd Announces Positive Phase-2 Results for Treatment of Atopic Dermatitis and Associated Pruritus
Posted: 11 June 2025 Positive top-line results from a Phase 2 clinical trial were announced by Akaal Pharma Pty Ltd (Akaal Pharma), a biopharmaceutical company focused on novel therapies for inflammatory and autoimmune skin disorders. The multicenter, randomized,…
Peter MacCallum Cancer Centre Announces Promising Prostate Cancer Therapy Results
Posted: 11 June 2025 Peter MacCallum Cancer Centre revealed highly encouraging initial results from its groundbreaking Terbium-161 prostate cancer therapy. The findings were presented at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting in Chicago and…
Chimeric Therapeutics’ CHM CDH17 Granted FDA Fast Track Designation
Posted: 10 June 2025 Chimeric Therapeutics (ASX:CHM) announced that the US Food and Drug Administration (FDA) had granted Fast Track Designation to CHM CDH17. This designation was based on the FDA’s assessment of CHM CDH17’s potential to improve…
NRFC Invests $27 Million in PolyActiva to Combat Glaucoma
Posted: 10 June 2025 The National Reconstruction Fund Corporation (NRFC) committed $27 million to PolyActiva as part of its $40 million Series C round. PolyActiva, a Melbourne-based biotechnology company, was developing a potentially revolutionary eye implant technology to…
Navigating the complexity of biologics and radiopharmaceuticals
Posted: 6 June 2025 This article summarises key insights from BioMelbourne Network’s BioForum, which brought together experts and participants to explore innovation, potential and challenges in complex biologics and radiopharmaceuticals. With around 90 participants in person and almost…
